Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Portland, Oregon 97239


Purpose:

This research project will determine the safety and tolerability of ginseng in subjects with MS and will gather preliminary data on the efficacy of ginseng vs placebo for the treatment of MS fatigue.


Study summary:

Fatigue is a major cause of disability in MS and is associated with a reduced quality of life. Treatment options for MS fatigue include central nervous system stimulants and amantadine. These medications are of limited efficacy, are often poorly tolerated, and can be expensive. Ginseng may represent a novel approach to treating MS fatigue. Ginseng has been tested in clinical trials for its ability to improve mental alertness and fatigue. However, there have been no published clinical trials addressing the effects of ginseng in subjects with MS, even though many people with MS use ginseng and report deriving benefit from it. This double-blinded, placebo controlled crossover pilot study will determine the safety and tolerability of ginseng in subjects with MS and will gather preliminary data on the efficacy of ginseng vs. placebo for the treatment of MS fatigue. Additionally, the project will collect information on the impact of ginseng on cognition, stress, actigraphy, salivary cortisol, differential cytokine response, and quality of life.


Criteria:

Inclusion Criteria: - MS as diagnosed by the McDonald criteria - Complaint of fatigue that has been persistent for at least 2 months - FSS score of 4 or greater; - Age 18-70. Exclusion Criteria: - Use of ginseng or stimulants in the prior 6 weeks - Acute treatment with glucocorticoids in the prior 6 weeks - BDI >31 - Significant MS exacerbation in prior 30 days - Diabetes - Uncontrolled hypertension - Other serious medical disease, pregnancy or breastfeeding - Breast disease - Abnormal bleeding or clotting disorder - Current use of warfarin, albendazole, nifedipine, digoxin, bumetadine, selegiline, isocarboxazid, or phenelzine - Current use of lasix for poorly controlled hypertension or congestive heart failure - Current drug or alcohol abuse; inability to complete the self report forms


NCT ID:

NCT00754832


Primary Contact:

Principal Investigator
Ruth Whitham, M.D.
Oregon Health and Science University


Backup Contact:

N/A


Location Contact:

Portland, Oregon 97239
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.